PR Newswire
14 Nov 2022, 17 GMT+10
ABERDEEN, Scotland and SINGAPORE, Nov. 14, 2022 /PRNewswire/ -- TauRx Pharmaceuticals Ltd is a global leader in tau-based research in Alzheimer's disease (AD). Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. It is a hallmark of the disease recognised as an important potential target for treating AD. HMTM is an oral tau aggregation inhibitor, targeting this underlying pathology.
Glenn Corr, Chief Operating Officer and Chief Business Officer said: "We appreciate the continued support of our shareholders as evidenced by their exercise of warrants. This represents a firm commitment to our mission - 'To discover, develop, and commercialise innovative products for the diagnosis and treatment of neurodegenerative diseases caused by protein aggregation'. Beyond funding regulatory submissions in the UK, US and Canada, this investment will also advance development plans for regulatory approval in China."
The positive outcome of this funding round, with more than 99% of warrants exercised, was triggered by the announcement of Phase 3 LUCIDITY (NCT03446001) topline data and adds to USD64 million raised in 2021 through a previous rights issue.
TauRx, supported by its group of strategic advisors, are moving forward in the regulatory submission process. This represents a monumental success for UK-based life sciences research and has potential to deliver a much-needed additional treatment option for the millions of people with Alzheimer's.
On Monday, 14 November, TauRx will present at the LSX Inv$tival conference in London and attend the Jefferies Healthcare conference later in the week. Results from the LUCIDITY trial will be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in San Francisco on 30 November.
ABOUT LUCIDITY
LUCIDITY is the only late-stage clinical trial specifically targeting the tau pathology of Alzheimer's. Aggregation of abnormal tau protein is one of the hallmark pathologies.
https://www.luciditytrial.com
ABOUT TAURx PHARMACEUTICALS LTD
The TauRx group of companies was established in 2002 in Singapore, continuing a partnership with the University of Aberdeen, with primary research facilities and operation based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer's and other neurodegenerative diseases due to protein aggregation pathology.
TauRx plans to submit HMTM for regulatory approval in the UK, US and Canada in 2023, with other territories to follow, in line with its overall plans to commercialise HMTM and pursue clinical trials in other related neurodegenerative diseases.
https://www.taurx.com
LinkedIn: https://www.linkedin.com/company/taurx-therapeutics
Youtube: https://www.youtube.com/user/TauRxTherapeutics
Twitter: https://twitter.com/TauRx
Get a daily dose of Asia Bulletin news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Bulletin.
More InformationNEW YORK CITY, New York: After being convicted of stealing more than $900,000 from the company, Rosita Joseph, former executive ...
WASHINGTON D.C.: The US State Department has said that in the latest fiscal year, US military equipment exported to foreign ...
MACAU CITY, Macau: Over the Lunar New Year holiday, Macau, the world's largest gambling hub, witnessed a resurgence of tourists ...
WASHINGTON D.C.: Republican US Senator Josh Hawley has said that he plans to introduce a bill to ban the use ...
WASHINGTON D.C.: This week, the US Food and Drug Administration (FDA) proposed significant limits on levels of lead in processed ...
WASHINGTON, D.C.: Finland and Sweden are prepared to join the NATO alliance, the U.S. State Department announced this week.The move ...
AUSTIN, Texas: Tesla gas announced an investment of more than $3.6 billion to expand its Nevada Gigafactory complex with the ...
WASHINGTON D.C.: US Senate Energy and Natural Resources Committee chair Joe Manchin has introduced legislation that imposes battery sourcing requirements ...
SINGAPORE: In December, Singapore saw its key consumer price gauge rise 5.1 percent, higher than predicted, official data said. However, ...
RESTON, Virginia: Amidst labor and supply shortages, US defense contractor General Dynamics forecasted weak 2023 results, though strong demand for ...
ATLANTA, Georgia: In light of its significant debt, the slowing economy and rising interest rates stifling consumer demand, US mattress-maker ...
BENTONVILLE, Arkansas: To attract and retain employees in a tight domestic labor market, Walmart has announced that it it will ...